Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. - Wikidata - wikimedia - TriplyDB

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.

http://www.wikidata.org/entity/Q35050554

about

Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.Brentuximab vedotin: clinical updates and practical guidance.Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.

P2860

Q36371623-759CDF58-A75E-4203-B145-24D6FA42166B Q38812806-17FFF94D-02F1-40A3-A4BF-58B789EB4439 Q38951604-CA9FF3CA-301E-47D7-B96C-CE844BF2B284 Q39132041-E6DBF343-5259-413D-9A79-5A901A179C96 Q39530535-884E213D-4E05-4E10-90FC-21A436371C05 Q47130656-3D0259CC-398B-4643-AA83-12F343DA14FF Q49282959-50A19513-5797-4E89-8199-35C2BF54A284 Q50044569-4F1FCB50-2D3A-452F-AD75-E29BCCA9899C Q50271165-489233DD-0492-487D-B350-998B46C6C693 Q52779365-9F557673-6043-43F2-AF2B-95E722BCA996

P2860

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.

http://www.wikidata.org/entity/Q35050554

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.

@ast

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.

@en

type

label

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.

@ast

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.

@en

prefLabel

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.

@ast

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.

@en

P1433

Q35050554-9C5F26DA-2717-4617-8394-054CC02C7F2C

P1476

Q35050554-730AE633-599C-47EC-9E57-3E641C2A484E

P2093

Q35050554-06CFF993-CD94-4CF6-B60C-B37C3BA85E0A

Q35050554-1412E111-CF48-4022-9089-153CA64ACCAA

Q35050554-209C7CE5-F6EC-417E-9D33-3BAFBE2F9D4F

Q35050554-28FB68B3-E0C5-4189-B0ED-A644B3DCD166

Q35050554-2A8D91BB-C9F3-4E07-9841-7CA0C586D4F2

Q35050554-38230961-82BE-49D8-BDF8-DA8EEAE19B46

Q35050554-49595B8F-54B6-4FA4-BA6D-CF967F0A4D70

Q35050554-53B3247E-D09B-4DA5-B9E6-A849E82C22F3

Q35050554-56DA2F62-8E60-40B0-92FA-45F69E96E307

Q35050554-7619E380-14EE-4374-916B-1DA1E919F7C4

P2860

Q35050554-25C7778E-9254-4BF5-88EA-639F86158AD7

Q35050554-2A2214E1-E6C3-4C8E-BED0-CC7E7BF486AE

Q35050554-36750A7B-1FE0-43C9-8C70-4784349BDE89

Q35050554-452F7FB9-CDEE-44CB-BF75-C39465EB4940

Q35050554-6F98F622-03C0-4C2D-9B6E-B15C426AEE6E

Q35050554-DD0BB378-6780-4B90-A9A6-1200A9AA4A55

Q35050554-EDD6E7A2-E017-4680-891F-23BD2488B6B6

Q35050554-FC017036-F309-4A50-9081-6A38CE50E65C

P304

Q35050554-BD235F4E-357B-4E1A-8AF4-783022F7E4EC

P31

Q35050554-40395DD4-5F61-4F66-B8AF-8271731E14F0

P356

Q35050554-297F097B-8ED5-48B9-A2B1-946B7FB22812

P433

Q35050554-75C1C931-0310-49A8-B7BB-4F4FBC2996A7

P478

Q35050554-EDBE0086-D408-4AC7-B14D-C1DF7518C281

P50

Q35050554-564802F8-914E-4610-9CA7-7E7F24AA01F2

Q35050554-6699C5B8-89F7-4E64-AA59-9D6F067BAA05

Q35050554-70C89263-8019-4EA5-9F0B-39039DC6063F

P577

Q35050554-0043BCCE-C540-4E02-8DD6-6E7E58F17FBE

P5875

Q35050554-E8BE3D7F-02AB-40DC-B7F2-5002C7CFB26A

P698

Q35050554-3FF20425-EA46-4340-B27F-90A4DB028F87

P932

Q35050554-E8AEDFF7-470F-4355-96D8-B1EA58E05DC4

P356

S00277-014-2215-9

P1433

Annals of Hematology

P1476

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey

@en

P2093

A Salihoglu

http://www.w3.org/2001/XMLSchema#string

E Birtas

http://www.w3.org/2001/XMLSchema#string

E Ozdemir

http://www.w3.org/2001/XMLSchema#string

G Akyol

http://www.w3.org/2001/XMLSchema#string

G Erdem

http://www.w3.org/2001/XMLSchema#string

G Sucak

http://www.w3.org/2001/XMLSchema#string

H Goker

http://www.w3.org/2001/XMLSchema#string

I Karadogan

http://www.w3.org/2001/XMLSchema#string

M Ozcan

http://www.w3.org/2001/XMLSchema#string

N Karadurmus

http://www.w3.org/2001/XMLSchema#string

P2860

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center

Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials

Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.

18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.

Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.

Revised response criteria for malignant lymphoma.

P304

415-420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-014-2215-9

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

Leylagul Kaynar

P577

2014-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265792846

http://www.w3.org/2001/XMLSchema#string

P698

25231929

http://www.w3.org/2001/XMLSchema#string

P932

4317523

http://www.w3.org/2001/XMLSchema#string